New side effect of weight loss injections

According to a press release from the UK's health regulator (MHRA), the package inserts for all glucagon-like peptide-1 (GLP-1) receptor agonists now include information about the risk of developing severe pancreatitis. 

Glucagon-like peptide-1 (GLP-1) receptor agonists are used to treat type 2 diabetes, manage weight, and prevent cardiovascular disease. In the UK, these medications include semaglutide, exenatide, dulaglutide, and tirzepatide. 

Acute pancreatitis (AP) is a sudden, dangerous inflammation of the pancreas, in which its own enzymes begin to digest the pancreas itself rather than food. This process causes pain and nausea. 

Acute pancreatitis is a recognized adverse event associated with the use of the above-mentioned medications. It is uncommon but can lead to very serious consequences. Therefore, the UK regulator is focusing its attention on this adverse event. 

According to the MHRA, 1,296 cases of glucagon-like peptide-1 (GLP-1) receptor agonists were reported between 2007 and 2025, 19 of which were fatal, and 24 resulted in gastrointestinal tissue necrosis. It is estimated that approximately 25.4 million packs of GLP-1 agonists have been sold over the past five years. 

In its early stages, pancreatitis can be difficult to diagnose, as its symptoms (nausea, abdominal pain, vomiting) can be mistaken for common side effects of the aforementioned medications or for infectious diseases. Therefore, healthcare providers should be extremely vigilant in monitoring patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, and patients should seek medical attention immediately at the first sign of adverse symptoms.